Trintellix Approval History
- FDA approved: Yes (First approved September 30th, 2013)
- Brand name: Trintellix
- Generic name: vortioxetine
- Previous name: Brintellix
- Company: Takeda Pharmaceuticals U.S.A., Inc.
- Treatment for: Depression, Major Depressive Disorder
Trintellix (vortioxetine) is a multimodal antidepressant for the treatment of major depressive disorder (MDD).
On May 2, 2016, Takeda Pharmaceuticals U.S.A., Inc. announced that Brintellix (vortioxetine) will be marketed under the new name Trintellix (vortioxetine) effective June 2016. The name change comes after reports of name confusion in the marketplace between Brintellix and the anti-blood clotting therapy Brilinta (ticagrelor).
Development History and FDA Approval Process for Trintellix
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.